Amylyx price target lowered to $42 from $47 at BofA

BofA lowered the firm’s price target on Amylyx to $42 from $47 and keeps a Buy rating on the shares after Relyvrio’s Q3 sales of $103M came in modestly below expectations. The firm doesn’t anticipate a major growth inflection in Q4, but expects a modest improvement starting in 2024 and overall thinks “there’s a lot to like about Amylyx at current valuation,” the analyst tells investors.